Compare Mercadolibre Inc (MELI) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mercadolibre Inc vs Viatris Inc — how do they compare? Mercadolibre Inc trades at $1,877 (market cap $98.35B), while Viatris Inc trades at $16.3 (market cap $18.69B). The key difference: Mercadolibre Inc is far larger — about 5.3× Viatris Inc's market cap, and Viatris Inc pays a 2.95% dividend while Mercadolibre Inc pays none. Which is the better fit depends on your goals.
| MELI | VTRS | |
|---|---|---|
Market Cap | $98.35B | $18.69B |
Sector | Consumer Cyclical | Health |
52-Week High | $2.51K | $17.86 |
52-Week Low | $1.55K | $9.49 |
Enterprise Value | $106.00B | $30.80B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MercadoLibre (MELI) trades at $1,824.34, up 0.2% with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $9.19, beating estimates by 6.2%, while revenue grew 50% year-over-year. Operating cash flow reached $12.12 billion in 2025, supporting aggressive growth investments. Analyst consensus remains strongly bullish with a $2,150 price target, though margin compression from strategic spending presents near-term headwinds.
MELI's growth-first strategy drives market share gains but pressures profitability, with net margin declining to 5.3%. The stock offers 18% upside to consensus target but faces execution risk in balancing expansion with returns. Competitive threats from global e-commerce players and Latin American economic volatility require monitoring. Long-term prospects remain positive given ecosystem strength and dominant market position.
Viatris (VTRS) trades at $16.28, down 0.91% on the day, with a bearish technical signal and mixed fundamentals. The company reported a net loss of $3.51 billion in 2025 despite recent quarterly earnings beats, including Q2 2026 EPS of $0.69 versus $0.62 expected. Revenue declined to $14.30 billion in 2025, but operational cash flow remains strong at $2.32 billion. Recent news highlights divestitures and FDA approval for Gwyn Lo, a contraceptive patch.
Outlook is cautious due to persistent losses and high P/E of 236.2, but dividend payments and cost-cutting efforts offer stability. Risks include competitive pressures and debt levels, while analyst consensus leans hold. The stock's value hinges on margin improvement and debt reduction progress.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mercadolibre Inc
MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
Read more on MELI →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
